JP5464856B2 - ジャスモネートの化学的誘導体、医薬組成物及びこれらの使用方法 - Google Patents

ジャスモネートの化学的誘導体、医薬組成物及びこれらの使用方法 Download PDF

Info

Publication number
JP5464856B2
JP5464856B2 JP2008544002A JP2008544002A JP5464856B2 JP 5464856 B2 JP5464856 B2 JP 5464856B2 JP 2008544002 A JP2008544002 A JP 2008544002A JP 2008544002 A JP2008544002 A JP 2008544002A JP 5464856 B2 JP5464856 B2 JP 5464856B2
Authority
JP
Japan
Prior art keywords
cancer
group
unsubstituted
substituted
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008544002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009519907A (ja
JP2009519907A5 (https=
Inventor
カシュマン、ヨエル
フレッシャー、エリーザー
ヘルツベルグ、エム．
Original Assignee
ラモト アット テル − アビブ ユニバーシティー リミテッド
セパル ファーマ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラモト アット テル − アビブ ユニバーシティー リミテッド, セパル ファーマ リミテッド filed Critical ラモト アット テル − アビブ ユニバーシティー リミテッド
Publication of JP2009519907A publication Critical patent/JP2009519907A/ja
Publication of JP2009519907A5 publication Critical patent/JP2009519907A5/ja
Application granted granted Critical
Publication of JP5464856B2 publication Critical patent/JP5464856B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/32—Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/385—Saturated compounds containing a keto group being part of a ring
    • C07C49/487—Saturated compounds containing a keto group being part of a ring containing hydroxy groups
    • C07C49/493—Saturated compounds containing a keto group being part of a ring containing hydroxy groups a keto group being part of a three- to five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/007—Esters of unsaturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/716—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2008544002A 2005-12-07 2006-12-07 ジャスモネートの化学的誘導体、医薬組成物及びこれらの使用方法 Active JP5464856B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74287505P 2005-12-07 2005-12-07
US60/742,875 2005-12-07
US77256706P 2006-02-13 2006-02-13
US60/772,567 2006-02-13
PCT/IL2006/001408 WO2007066336A2 (en) 2005-12-07 2006-12-07 Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013109643A Division JP2013199483A (ja) 2005-12-07 2013-05-24 ジャスモネートの化学的誘導体、医薬組成物及びこれらの使用方法

Publications (3)

Publication Number Publication Date
JP2009519907A JP2009519907A (ja) 2009-05-21
JP2009519907A5 JP2009519907A5 (https=) 2010-01-28
JP5464856B2 true JP5464856B2 (ja) 2014-04-09

Family

ID=38038558

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008544002A Active JP5464856B2 (ja) 2005-12-07 2006-12-07 ジャスモネートの化学的誘導体、医薬組成物及びこれらの使用方法
JP2013109643A Pending JP2013199483A (ja) 2005-12-07 2013-05-24 ジャスモネートの化学的誘導体、医薬組成物及びこれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013109643A Pending JP2013199483A (ja) 2005-12-07 2013-05-24 ジャスモネートの化学的誘導体、医薬組成物及びこれらの使用方法

Country Status (9)

Country Link
US (1) US20090291904A1 (https=)
EP (3) EP2617714B1 (https=)
JP (2) JP5464856B2 (https=)
AU (1) AU2006322844A1 (https=)
BR (1) BRPI0619492A2 (https=)
CA (1) CA2632653C (https=)
DK (1) DK2617714T3 (https=)
ES (1) ES2576980T3 (https=)
WO (1) WO2007066336A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013199483A (ja) * 2005-12-07 2013-10-03 Ramot At Tel-Aviv Univ Ltd ジャスモネートの化学的誘導体、医薬組成物及びこれらの使用方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9284274B2 (en) * 2005-12-07 2016-03-15 Ramot At Tel-Aviv University Ltd. Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
CA2657375A1 (en) * 2006-07-10 2008-01-17 Ramot At Tel-Aviv University Ltd. Combination methods of treating cancer
WO2008111088A2 (en) 2007-03-15 2008-09-18 Ramot At Tel-Aviv University Ltd. Jasmonate based assays for identifying compounds that selectively inhibit mitochondrial bound hexokinases
US9284252B2 (en) 2009-06-09 2016-03-15 Sepal Pharma Ltd. Use of jasmonate ester derivatives for treating benign hyperproliferative skin disorders
RU2623878C2 (ru) 2010-12-10 2017-06-29 Броади Хэлс Сайенсис, Эл Эл Си Применение жасмоната для лечения нарушения функции мочевого пузыря
WO2013040556A1 (en) 2011-09-16 2013-03-21 Nanocare Technologies, Inc. Compositions of jasmonate compounds and methods of use
JP6081873B2 (ja) * 2013-06-24 2017-02-15 旭化成ファインケム株式会社 界面活性剤
CA2971870A1 (en) * 2014-12-31 2016-07-07 Nanocare Technologies, Inc. Jasmonate derivatives and compositions thereof
WO2017168416A1 (en) 2016-03-28 2017-10-05 Vidac Pharma Ltd. Stable pharmaceutical compositions for topical administration and uses thereof
AU2017311691B2 (en) 2016-08-18 2021-12-02 Vidac Pharma Ltd. Piperazine derivatives, pharmaceutical compositions and methods of use thereof
US11266639B2 (en) 2016-11-07 2022-03-08 Vidac Pharma Ltd. Use of hexokinase 2/mitochondria-detaching compounds for treating hexokinase-2 (HK2)-expressing cancers
WO2018083704A1 (en) 2016-11-07 2018-05-11 Vidac Pharma Ltd. Use of hexokinase 2/mitochondria-detaching compounds for activating immune responses
WO2019135243A1 (en) * 2018-01-07 2019-07-11 Vidac Pharma Ltd Methods for preparation of jasmonate compounds
CN113768911B (zh) * 2021-10-20 2023-10-27 郑州大学 Apobec3b抑制剂及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3981891A (en) * 1972-01-18 1976-09-21 Societe Anonyme Roure Bertrand Dupont Cyclopentanone derivatives, odoriferous compositions containing them and process of preparation thereof
FR2168147B1 (https=) * 1972-01-18 1974-11-08 Roure Bertrand Dupont Sa
ZA747723B (en) * 1974-12-11 1976-11-24 Pfizer 11-desoxy-15-substituted-omega-pentanor prostaglandins
US3932389A (en) * 1974-12-11 1976-01-13 Pfizer Inc. 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorprostaglandins
US4154949A (en) * 1974-12-11 1979-05-15 Pfizer Inc. 11-Desoxy-15-substituted-ω-pentanor prostaglandins
JPH06122653A (ja) * 1992-08-25 1994-05-06 Japan Tobacco Inc 飽和単環炭化水素化合物の製造方法およびその中間体
US5476945A (en) * 1992-11-17 1995-12-19 Fuji Photo Film Co., Ltd. Water-soluble methine derivatives of thiazole
US5637484A (en) * 1993-11-15 1997-06-10 Mitsui Petrochemical Industries, Ltd. Method of producing a taxane-type diterpene and a method of obtaining cultured cells which produce the taxane-type diterpene at a high rate
JP4041186B2 (ja) * 1997-07-09 2008-01-30 独立行政法人科学技術振興機構 ファイトアレキシン誘導剤
JPH11140022A (ja) * 1997-11-12 1999-05-25 Nippon Zeon Co Ltd ジャスモン酸系化合物とその製法
JPH11139908A (ja) * 1997-11-12 1999-05-25 Nippon Zeon Co Ltd ジャスモン酸系化合物を含有する寄生植物用発芽誘導剤
JP3815919B2 (ja) * 1999-05-26 2006-08-30 三井化学株式会社 タキサン型ジテルペンの製造方法
US20030219461A1 (en) * 2000-09-12 2003-11-27 Britten Nancy J. Parenteral combination therapy for infective conditions
WO2002076439A2 (en) * 2001-03-23 2002-10-03 The Board Of Trustees Of The University Of Illinois Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same
US6469061B1 (en) * 2001-04-04 2002-10-22 Ramot University Authority For Applied Research And Industrial Development Limited Jasmonate pharmaceutical composition for treatment of cancer
FR2825926A1 (fr) * 2001-06-14 2002-12-20 Sod Conseils Rech Applic Derives d'imidazoles modulant les canaux sodiques
FR2835525B1 (fr) * 2002-02-04 2006-02-10 Oreal Nouveaux composes, compositions les comprenant et leur utilisation pour favoriser la desquamation
FR2835526B1 (fr) * 2002-02-04 2006-02-10 Oreal Nouveaux composes, compositions les comprenant et leur utilisation pour favoriser la desquamation
US20030224024A1 (en) * 2002-02-04 2003-12-04 Jean-Luc Leveque Compositions comprising cyclopentane derivatives and their use
US7460960B2 (en) * 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
FR2843125B1 (fr) * 2002-08-02 2012-11-16 Coletica Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs
WO2004091516A2 (en) * 2003-04-10 2004-10-28 Johns Hopkins University Methods for controlling the proliferation of cells
CN1193979C (zh) * 2003-06-23 2005-03-23 华东理工大学 茉莉酮酸酯衍生物及其在植物细胞中的应用
WO2005054172A2 (en) 2003-12-02 2005-06-16 Ramot At Tel-Aviv University Ltd. Jasmonate derivative compounds, pharmaceuticals compositions and methods of use thereof
US7026279B2 (en) * 2004-06-24 2006-04-11 International Flavors & Fragrances Inc. Use of 3-(methoxymethyl)-2-pentylcyclopenta derivatives in perfume compositions
US20090291904A1 (en) * 2005-12-07 2009-11-26 Yoel Kashman Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013199483A (ja) * 2005-12-07 2013-10-03 Ramot At Tel-Aviv Univ Ltd ジャスモネートの化学的誘導体、医薬組成物及びこれらの使用方法

Also Published As

Publication number Publication date
ES2576980T3 (es) 2016-07-12
JP2013199483A (ja) 2013-10-03
WO2007066336A2 (en) 2007-06-14
US20090291904A1 (en) 2009-11-26
CA2632653C (en) 2014-11-04
DK2617714T3 (da) 2016-06-27
EP2617714A1 (en) 2013-07-24
WO2007066336A3 (en) 2007-12-27
AU2006322844A1 (en) 2007-06-14
JP2009519907A (ja) 2009-05-21
EP2402321A3 (en) 2012-02-29
EP2617714B1 (en) 2016-03-23
BRPI0619492A2 (pt) 2011-10-04
EP1960364A2 (en) 2008-08-27
EP2402321A2 (en) 2012-01-04
CA2632653A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
JP2013199483A (ja) ジャスモネートの化学的誘導体、医薬組成物及びこれらの使用方法
JP7449913B2 (ja) オキサチアジン様化合物を作製する方法
US12162868B2 (en) Piperazine derivatives, pharmaceutical compositions and methods of use thereof
JP2009520692A (ja) 改良されたジャスモネート誘導体、医薬組成物及びそれらの使用方法
US9284274B2 (en) Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
CN105294666B (zh) 一种丹参素衍生物及其制备方法和医药应用
JP7215774B2 (ja) 多機能標的免疫小分子抗癌薬のクエン酸ベスタゾミブおよびその製造方法と使用
CN103304573B (zh) 石蒜碱类化合物在制备抗肿瘤药物的应用
CN118891043A (zh) 包含脂质化合物的组合物以及制备和使用其的方法
KR20160111988A (ko) 신규한 cyp-아이코사노이드 유도체
CN118338914A (zh) 包含氨基脂质化合物的组合物以及制备和使用其的方法
FI83780C (fi) Foerfarande foer framstaellning av terapeutiskt aktiva (tio) flavener.
KR101629077B1 (ko) 편평세포 암종 및 간암에 대한 억제제인 스틸베노이드 화합물 및 그의 용도
IL229418A (en) Derivatives of gasmont, pharmaceutical preparations and their use
CN101336233A (zh) 茉莉酮酸酯化学衍生物、其药物组合物及使用方法
JP2003055373A (ja) Ｃ７エステル置換タキサン
CN108546268A (zh) 用于治疗动脉粥样硬化的化合物及其应用
JP2016533329A (ja) Δ１２−ｐｇｊ３および関連化合物の合成
JP2010523498A (ja) セレクチンの阻害のための方法および組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091204

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120814

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130524

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130709

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140121

R150 Certificate of patent or registration of utility model

Ref document number: 5464856

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

S201 Request for registration of exclusive licence

Free format text: JAPANESE INTERMEDIATE CODE: R314201

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250